Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) (NCT07584031) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)
200 participantsStarted 2026-06-01
Plain-language summary
This is a prospective, single-center, randomized phase 2 study of adebrelimab plus full-course neoadjuvant therapy in resectable locally advanced esophageal squamous cell carcinoma. Patients achieving clinical complete response (cCR) after neoadjuvant treatment will be randomized 1:1 to watchful waiting with 2 cycles consolidation chemo-Immunotherapy or standard surgery. Primary endpoint is 2-year DFS. Secondary endpoints include OS, pCR/MPR, R0 resection rate, safety, and quality of life.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Complete blood count (CBC):
. Hemoglobin (Hb) ≥ 90 g/L (no blood transfusion within the past 14 days);
. Neutrophil count (NEUT) ≥ 1.5 × 10⁹/L;
. Platelet count (PLT) ≥ 100 × 10⁹/L;
. White blood cell count (WBC) ≥ 3 × 10⁹/L;
. Biochemical Tests:
. Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5×ULN;
. Serum total bilirubin (TBIL) ≤ 1.5×ULN;
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
2-year Disease-Free Survival (DFS) rate in the watchful waiting arm
Timeframe: Assessed from randomization to disease recurrence, progression, or death, up to 2 years
Trial details
NCT IDNCT07584031
SponsorTianjin Medical University Cancer Institute and Hospital
. Acute or recurrent myocardial ischemia or myocardial infarction; poorly controlled and clinically significant arrhythmias; and heart failure of Class II or higher (New York Heart Association \[NYHA\] functional class); LVEF (left ventricular ejection fraction) \< 50%;
. Active or uncontrolled severe infection (≥ Grade 2 CTC AE infection);